Fabry Disease Program (αGal)
Advancing a preclinical genetic therapy for Fabry Disease.
Executive Summary
The Fabry Disease Program (αGal) is a preclinical-stage genetic disease program by Relay Therapeutics, focused on developing a novel therapeutic for Fabry Disease. This rare, inherited disorder is caused by a deficiency of the enzyme alpha-galactosidase A (αGal), leading to the accumulation of harmful fatty substances in cells throughout the body. Relay Therapeutics is committed to addressing the significant unmet medical needs of patients suffering from this debilitating condition. Leveraging Relay Therapeutics' proprietary Dynamo platform, this program integrates cutting-edge computational and experimental approaches to identify and optimize drug candidates. The Dynamo platform is designed to understand protein motion and drug previously challenging targets, aiming to develop a precision medicine that can effectively treat the underlying cause of Fabry Disease. The program is currently undergoing rigorous preclinical studies to evaluate its efficacy, safety, and pharmacokinetic properties, paving the way for potential future clinical development.
Use Cases
- Treating Fabry Disease patients
- Addressing the underlying genetic cause of Fabry Disease
- Providing a novel therapeutic option for a rare genetic disorder
- Advancing precision medicine for genetic diseases
Features
Visibility
- Preclinical Data Visualization: Interactive dashboards to visualize experimental results, compound properties, and biological activity.
- Program Progress Tracking: Tools to monitor the advancement of the Fabry Disease program through preclinical stages.
Intelligence
- Molecular Dynamics Simulation: Advanced simulations to understand protein motion and identify druggable pockets.
- AI-Driven Target Identification: Algorithms to predict and validate novel therapeutic targets for Fabry Disease.
- Compound Optimization: Computational tools to guide the design and optimization of drug candidates.
Technical Specifications
- Architecture
- Proprietary Dynamo platform integrating computational chemistry, structural biology, and experimental data analysis for drug discovery.
- API Available
- No
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies. They focus on making small molecule medicines against precision medicine targets, with an initial focus on oncology and genetic disease.